Por Renan Filho · 2026-10-09
**Lead**
The World Health Organization (WHO) today issued a landmark statement confirming that glucagon-like peptide-1 (GLP-1) receptor agonists – commonly referred to as weight loss jabs – are safe for use in obese teenagers. The announcement, based on a comprehensive review of clinical trials and post‑market surveillance, is expected to reshape paediatric obesity treatment protocols globally, with particular significance for the United Kingdom, where adolescent obesity rates remain among the highest in Europe.
**Context**
The WHO’s decision follows years of debate over the off‑label use of drugs such as semaglutide (marketed as Wegovy and Ozempic) in younger populations. While these medications have been approved for adults in dozens of countries, their application in adolescents has been cautious due to concerns about long‑term effects on growth, metabolism, and psychological development.
In the UK, the National Institute for Health and Care Excellence (NICE) has already recommended semaglutide for teenagers aged 12 and above who meet strict criteria – including having a body mass index (BMI) above the 99th centile and at least one obesity‑related complication. However, uptake has been limited by lingering safety doubts among clinicians and parents. The WHO’s endorsement is likely to provide the authoritative reassurance needed to expand prescription rates and potentially lower the threshold for eligibility.
Obesity among British teenagers has reached concerning levels. Data from the National Child Measurement Programme indicates that approximately one in five children are classified as obese by the time they leave primary school, and the proportion rises through adolescence. The condition is linked to a higher risk of type 2 diabetes, cardiovascular disease, and mental health problems, placing an increasing burden on the NHS. Treatments have traditionally focused on lifestyle interventions, but success rates vary, and many young people fail to sustain weight loss through diet and exercise alone.
**Analysis**
Why does the WHO announcement matter now? The timing is critical. A wave of GLP‑1 drugs has flooded the pharmaceutical market, and manufacturers are actively pursuing paediatric indications. The WHO’s green light provides a unified global standard that national regulators, including the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), can rely on. It also encourages further research into adolescent‑specific dosing and side‑effect profiles, which have been less studied than in adults.
The implications for the NHS are profound. If incorporated into the NICE guidelines, the WHO statement could lead to a significant increase in prescriptions, potentially reducing the need for bariatric surgery in teenagers – an invasive procedure that carries its own risks. Moreover, early pharmacological intervention might prevent the establishment of lifelong obesity patterns, cutting future healthcare costs. However, experts caution that weight loss jabs are not a silver bullet. They must be paired with comprehensive behavioural support, including dietary counselling and physical activity programmes, to achieve durable outcomes. Side effects – such as nausea, vomiting, and gastrointestinal discomfort – are common, and long‑term safety data for use over many decades in adolescents remain sparse. The WHO has stressed that the medications should only be prescribed under specialist supervision.
**Sources**
The information in this article is based on the official statement released by the World Health Organization on 9 October 2026, alongside published guidance from the UK’s National Institute for Health and Care Excellence (NICE) and the Medicines and Healthcare products Regulatory Agency (MHRA). Additional context draws from the National Child Measurement Programme data and peer‑reviewed analyses of GLP‑1 receptor agonist trials in adolescent populations. No specific individuals or unpublished datasets were cited.